Immunocore is a commercial-stage biotechnology company with a mission to radically improve outcomes for patients living with cancer, infectious diseases, and autoimmune conditions by pioneering and delivering transformative medicines. In 2022 we launched the world’s first T cell receptor (TCR) therapy, ushering in a new era of cancer therapeutics. By unlocking >90% of cancer targets, our modular and off-the-shelf ImmTAC technology is designed to harness the natural immune system's power to fight multiple cancers and help address unmet needs.